Analysts’ downgrades for Friday, August 11th:
Blue Apron Holdings (NASDAQ:APRN) was downgraded by analysts at Citigroup Inc. from a buy rating to a neutral rating.
Blue Apron Holdings (NASDAQ:APRN) was downgraded by analysts at SunTrust Banks, Inc. from a buy rating to a hold rating.
CECO Environmental Corp. (NASDAQ:CECE) was downgraded by analysts at William Blair from an outperform rating to a market perform rating.
Masonite International Corporation (NYSE:DOOR) was downgraded by analysts at Stifel Nicolaus from a buy rating to a hold rating.
Forterra (NASDAQ:FRTA) was downgraded by analysts at Barclays PLC from an overweight rating to a hold rating.
Hudson Technologies (NASDAQ:HDSN) was downgraded by analysts at B. Riley from a buy rating to a neutral rating. They currently have $10.00 price target on the stock.
LTC Properties (NYSE:LTC) was downgraded by analysts at BMO Capital Markets from a market perform rating to an underperform rating.
Luxoft Holding (NYSE:LXFT) was downgraded by analysts at Wedbush from an outperform rating to a neutral rating.
Navios Maritime Acquisition Corporation (NYSE:NNA) was downgraded by analysts at Citigroup Inc. from a buy rating to a neutral rating.
Snap (NYSE:SNAP) was downgraded by analysts at Monness Crespi & Hardt from a buy rating to a neutral rating.
TPI Composites (NASDAQ:TPIC) was downgraded by analysts at J P Morgan Chase & Co from an overweight rating to a neutral rating.
Veritone (NASDAQ:VERI) was downgraded by analysts at Zacks Investment Research from a buy rating to a sell rating. According to Zacks, “Veritone, Inc. is an artificial intelligence company. It developed the Veritone Platform, which unlocks the power of AI-based cognitive computing to transform and analyze unstructured public and private audio and video data for clients in the media, politics, legal and law enforcement industries. Veritone, Inc. is based in Newport Beach, United States. “
Voyager Therapeutics (NASDAQ:VYGR) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Xencor (NASDAQ:XNCR) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “
